Yinghong Wang, M.D., Ph.D., M.S.
Department of Gastroenterology Hepatology and Nutrition, Division of Internal Medicine
About Dr. Wang
Dr. Wang has a strong academic background (M.D., Ph.D., M.Sc.) and profound clinical experience from world renowned medical programs (Johns Hopkins, Cleveland Clinic). She has broad research collaboration network worldwide and holds more than 100 peer-reviewed publications and numerous international conference presentations in her academic career. Her specialized areas include Inflammatory Bowel Disease (IBD), fecal microbiota transplantation (FMT), and cancer immunotherapy induced gastrointestinal toxicities.
Prior to joining The University of Texas MD Anderson Cancer Center, Dr. Wang had 8 years of experience from a tertiary IBD center at Cleveland Clinic taking care of patients with complex Crohn’s Disease, and Ulcerative Colitis with or without serious complications. In addition, Dr. Wang had 2 years of clinic experience doing FMT for recurrent C diff infection at Cleveland Clinic with a high eradication rate (>95%).
At MD Anderson, Dr. Wang has been recognized for her expertise in managing cancer immunotherapy induced GI toxicities and her initiative in setting up IBD clinic and FMT service. In addition to offering FMT as standard of care for recurrent Clostridioides difficile infections in cancer patients, she is taking a leading role on the management of immunotherapy related toxicities and serves as the chair of institutional immunotherapy toxicity working group. Over the past 3 years, she has served as guideline panel member for immunotherapy induced colitis in four national and international oncology societies and gastroenterology society (ASCO, SITC, NCCN, ESMO, AGA) and UPTODATE. Dr. Wang also leads the work of building detailed management algorithm of immunotherapy induced colitis at the institutional level ( https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/clinical-management/clin-management-immune-mediated-colitis-web-algorithm.pdf ) and published a new book entitled “Managing Immunotherapy Related Organ Toxicities, A Practical Guide” as the editor in 09/2022 ( https://link.springer.com/book/10.1007/978-3-031-00241-0 ). Dr. Wang and her team achieved a breakthrough of successful treatment for immunotherapy induced colitis refractory to immunosuppressant by FMT as a compassionate treatment. This pioneering work was published on Nature Medicine ( https://www.nature.com/articles/s41591-018-0238-9.pdf ), with great impact in this field (see press release https://www.mdanderson.org/newsroom/2018/11/fecal-transplant-effective-against-immunotherapy-induced-colitis.html ) with further expansion on the patient volume to > 35 cases with high efficacy of 83% up to year 2022. Over the past 5 years at MD Anderson, Dr. Wang and her collaborators among more than 10 other academic centers worldwide published >90 peer reviewed scientific articles in the oncology field in many prestigious journals e.g. New England Journal of Medicine, Annals of Internal Medicine, Journal of Clinical Oncology, JAMA Oncology etc investigating cancer and colitis outcomes among immunotherapy treated patients (see Journal of Clinical Oncology podcast http://ct.moreover.com/?a=39462129719&p=1pl&v=1&x=fEpn0W3Zs-Qgm5BaYVQbiA; http://jcopodcast.jcopodcast.libsynpro.com/a-second-chance-at-checkpoint-inhibition-after-initial-immune-mediated-diarrhea-and-colitis ).
Dr. Wang and her team have launched three clinical trials in treating colitis and are enrolling patients (NCT03819296, NCT04038619, NCT04407247). Among them, two trials are offering FMT on a larger scale patient population to maximize the benefit and minimize the morbidities related to immunosuppressant use such as steroid. Another clinical trial that she is participating together with Infectious Disease and Cancer Prevention Group is investigating the role of STAT3 in preventing cancer development in IBD patients, who are high risk population for colon cancer.
Patient education material for immunotherapy colitis management and clinical trials:
https://www.mdanderson.org/patient-education/Gastrointestinal/Fecal-Microbiota-Transplant.pdf
For your education on the immunotherapy induced colitis overview and treatment, please clink on the following link for PPT slides. URL: https://mediaplayer.mdanderson.edu/video-full/247F62CA-742A-4E64-A40F-42570B25A0DE.
Dr. Wang speaks English and Mandarin Chinese fluently.
Present Title & Affiliation
Primary Appointment
Director of Fecal Microbiota Transplantation, Department of Gastroenterology, Hepat,& Nutr, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of Inflammatory Bowel Disorders, Department of Gastroenterology, Hepat,& Nutr, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Chair of MD Anderson Institutional Immunotherapy Toxicity Working Group, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Wang has a strong academic background (M.D., Ph.D., M.Sc.) and profound clinical experience from world renowned medical programs (Johns Hopkins, Cleveland Clinic). She has broad research collaboration network worldwide and holds >100 peer-reviewed publications and numerous international conference presentations. Her specialized areas include Inflammatory Bowel Disease (IBD), fecal microbiota transplantation (FMT), and cancer immunotherapy induced gastrointestinal toxicities.
Since joining MD Anderson in 12/2016, Dr. Wang has been recognized internationally for her expertise in managing cancer immunotherapy induced GI toxicities. She served as guideline panel member in four national and international oncology societies and gastroenterology society (ASCO, SITC, NCCN, ESMO, AGA), UPTODATE immunotherapy GI toxicity chapter, and also the chair of MD Anderson institutional immunotherapy toxicity working group. She contributed a new book entitled “Managing Immunotherapy Related Organ Toxicities, A Practical Guide” as the editor in 09/2022 ( https://link.springer.com/book/10.1007/978-3-031-00241-0 ).
Dr. Wang and her team achieved multiple breakthroughs of successful treatment for immunotherapy induced colitis refractory to standard treatment and published her pioneer work on many prestigious journals such as NEJM, JCO, Nature Medicine with great impact to this field. Dr. Wang and her team have launched three clinical trials in treating colitis and are actively enrolling patients (NCT03819296, NCT04038619, NCT04407247). Among them, two trials are offering FMT on a larger scale patient population to maximize the benefit and minimize the morbidities related to immunosuppressant use such as steroid.
For your education on the immunotherapy induced colitis overview and treatment, please clink on the following link for PPT slides. URL: https://mediaplayer.mdanderson.edu/video-full/247F62CA-742A-4E64-A40F-42570B25A0DE.
Dr. Wang speaks English and Mandarin Chinese fluently.
Education & Training
Degree-Granting Education
| 2005 | Johns Hopkins University, Baltimore, MD, USA, PHD, Cellular & Molecular Physiology |
| 1999 | The University of Calgary, Calgary, CAN, MSc, Cardiovascular & Respiratory Sciences |
Postgraduate Training
| 2008-2011 | Clinical Fellowship, Gastroenterology, Cleveland Clinic Foundation, Cleveland, OH |
| 2005-2008 | Clinical Residency, Internal Medicine, Albany Medical Center, Albany, NY |
Board Certifications
| 2011 | Gastroenterology |
| 2008 | Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Gastroenterology, Hepat,& Nutr, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2021
Assistant Professor, Department of Gastroenterology, Hepat,& Nutr, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2019
Administrative Appointments/Responsibilities
Director of Medication Induced Colitis and Enteritis, Department of Gastroenterology, Hepat,& Nutr, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, Richards DM, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer 6(1):142, 2018. e-Pub 2018. PMID: 30518410.
- Choi K, Abu-Sbeih H, Samdani R, Nogueras Gonzalez G, Raju GS, Richards DM, Gao J, Subudhi S, Stroehlein J, Wang Y. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?. Inflamm Bowel Dis. e-Pub 2018. PMID: 30169584.
- Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh VA, Zobniw C, Johnson DH, Samdani R, Lum P, Shuttlesworth G, Blechacz B, Bresalier R, Miller E, Thirumurthi S, Richards D, Raju G, Stroehlein J, Diab A. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflamm Bowel Dis 24(8):1695-1705, 2018. PMID: 29718308.
- Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714-1768, 2018. e-Pub 2018. PMID: 29442540.
- Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, Lum P, Raju G, Shuttlesworth G, Stroehlein J, Diab A. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 6(1):37, 2018. e-Pub 2018. PMID: 29747688.
- Wang Y, Aggarwal P, Liu X, Lu H, Lian L, Wu X, Guo S, Aggarwal N, Lashner B, Shen B. Antiviral Treatment for Colonic Cytomegalovirus Infection in Ulcerative Colitis Patients Significantly Improved Their Surgery Free Survival. J Clin Gastroenterol 52(4):e27-e31, 2018. PMID: 27875354.
- Abu-Sbeih h, Tang T, Ali F, Qiao W, Diab A, Wang Y. The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’ outcomes. J Immunother Precis Oncol 1(1):7-18, 2018.
- Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS, Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95, 2017. e-Pub 2017. PMID: 29162153.
- Mehta PP, Kochhar G, Albeldawi M, Kirsh B, Rizk M, Putka B, John B, Wang Y, Breslaw N, Lopez R, Vargo JJ. Capnographic Monitoring in Routine EGD and Colonoscopy With Moderate Sedation: A Prospective, Randomized, Controlled Trial. Am J Gastroenterol 111(3):395-404, 2016. e-Pub 2016. PMID: 26902229.
- Lai KK, Horvath B, Xie H, Wu X, Lewis BL, Pai RK, Plesec T, Patil DT, Gordon IO, Wang Y, Shen B, Goldblum JR, Liu X. Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia. Inflamm Bowel Dis 21(2):378-84, 2015. PMID: 25569733.
- Xie H, Xiao SY, Pai R, Jiang W, Shadrach B, Carver P, Wang Y, Shen B, Zhou W, Liu X. Diagnostic utility of TP53 and cytokeratin 7 immunohistochemistry in idiopathic inflammatory bowel disease-associated neoplasia. Mod Pathol 27(2):303-13, 2014. e-Pub 2013. PMID: 23887291.
- Wang Y, Atreja A, Wu X, Lashner BA, Brzezinski A, Shen B. Similar outcomes of IBD inpatients with Clostridium difficile infection detected by ELISA or PCR assay. Dig Dis Sci 58(8):2308-13, 2013. e-Pub 2013. PMID: 23525735.
- Wang Y, Gong H, Lopez R, Lian L, Kiran RP, Soffer EE, Shen B. Correlation between serum serotonin and endoscopy inflammation scores in patients with ileal pouches. J Crohns Colitis 7(4):e133-42, 2013. e-Pub 2012. PMID: 22922006.
- Wang Y, Lee H, Shen B. Systemic secondary amyloidosis in a 70-year-old patient with Crohn's disease: treatment with oral budesonide. Inflamm Bowel Dis 19(5):E74-5, 2013. PMID: 23478807.
- Wang Y, Bennett AE, Cai H, Lian L, Shen B. Evaluation of upper and lower gastrointestinal histology in patients with ileal pouches. J Gastrointest Surg 16(3):572-80, 2012. e-Pub 2011. PMID: 22052108.
- Wang Y, Shen B. Clostridium difficile-associated diarrhea in Crohn's disease patients with ostomy. Inflamm Bowel Dis 16(1):1-2, 2010. PMID: 19408324.
- Cai H, Cebotaru V, Wang YH, Zhang XM, Cebotaru L, Guggino SE, Guggino WB. WNK4 kinase regulates surface expression of the human sodium chloride cotransporter in mammalian cells. Kidney Int 69(12):2162-70, 2006. e-Pub 2006. PMID: 16688122.
- Wang Y, Cai H, Cebotaru L, Hryciw DH, Weinman EJ, Donowitz M, Guggino SE, Guggino WB. ClC-5: role in endocytosis in the proximal tubule. Am J Physiol Renal Physiol 289(4):F850-62, 2005. e-Pub 2005. PMID: 15942052.
- Hara-Chikuma M, Wang Y, Guggino SE, Guggino WB, Verkman AS. Impaired acidification in early endosomes of ClC-5 deficient proximal tubule. Biochem Biophys Res Commun 329(3):941-6, 2005. PMID: 15752747.
- Hryciw DH, Wang Y, Devuyst O, Pollock CA, Poronnik P, Guggino WB. Cofilin interacts with ClC-5 and regulates albumin uptake in proximal tubule cell lines. J Biol Chem 278(41):40169-76, 2003. e-Pub 2003. PMID: 12904289.
- Fewell JE, Smith FG, Ng VK, Wong VH, Wang Y. Postnatal age influences the ability of rats to autoresuscitate from hypoxic-induced apnea. Am J Physiol Regul Integr Comp Physiol 279(1):R39-46, 2000. PMID: 10896862.
Abstracts
- Ali FS, Abu-Sbeih H, Hicklen R, Wang Y. Fearing the Unknown – The Fate of Inflammatory Bowel Disease after Fecal Microbiota Transplantation in Clostridium difficile Infection. American College of Gastroenterology Annual Conference, 2018.
- Abu-Sbeih H, Ali FS, Hicklen R, Wang Y. Fecal Microbiota Transplantation for Clostridium difficile Infection in Immunocompromised Patients – Safe or Risky?. American College of Gastroenterology Annual Conference, 2018.
- Abi-Sbeih H, Ali FS, Hicklen R, Wang Y. Taming the Beast – The Safety and Efficacy of Fecal Microbiota Transplantation in Severe and Complicated Clostridium Difficile Infectino. American College of Gastroenterology Annual Conference, 2018.
- Choi K, Abu-Sbeih H, Samdani R, Gonzalez GN, Raju GS, Richards D, Gao J, Subudhi S, Stroehlein J, Wang Y. Features of Microscopic Colitis in Cancer Patients Receiving Immune Checkpoint Inhibitors. American College of Gastroenterology Annual Conference, 2018.
- Abu-Sbeih H, Ali F, Alsaadi D, Jennings J, Luo W, Gong Z, Richards D, Charabaty A, Wang Y. Outcomes of vedolizumab treatment in patients with immune checkpoint inhibitor induced diarrhea and colitis: A Multi-Center Study. American College of Gastroenterology Annual Conference oral presentation, 2018.
- Tang T, Abu-Sbeih H, Luo W, Samdani R, Lum P, Qiao W, Bresalier, Richards D, Wang Y. The Constellation of Upper Gastrointestinal Symptoms and associated Endoscopic and Histologic Features in Patients Receiving Immune Checkpoint Inhibitors. American College of Gastroenterology Annual Conference, 2018.
- Abu-Sbeih H, Ali FS, Qiao W, Lu Y, Patel S, Diab A, Wang Y. The Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor Induced Colitis. American College of Gastroenterology Annual Conference, 2018.
- Abu-Sbeih H, Ali FS, Qiao W, Raju GS, Wang Y. Immune Checkpoint Inhibitor–Induced Colitis as a Predictor of Survival in Metastatic Melanoma. Society for Immunotherapy of Cancer, 2018.
- Abu-Sbeih H, Tang T, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. Society for Immunotherapy of Cancer, 2018.
- Abu-Sbeih H, Ali FS, Gao J, Wang Y. The fate of immune–mediated diarrhea after the resumption of immune checkpoint inhibitor treatment. Society for Immunotherapy of Cancer, 2018.
- Wang Y, Abu-Sbeih H, Choi K, Wiesnoski D, Helmink B, Gopalakrishnan V, DuPont H, Jiang ZD, Tetzlaff M, Wargo J, Jeng RR. Fecal Microbiota Transplantation for refractory immune checkpoint inhibitor-associated colitis. Society for Immunotherapy of Cancer, 2018.
- Abu-Sbeih H, Tang T, Richards DM, Westin JR, Neelapu SS Wang Y. Gastrointestinal symptoms observed after chimeric antigen receptor T–cell therapy. Society for Immunotherapy of Cancer, 2018.
- Zhang CH, Luo W, Wang Y. Acute Liver Injury in the Context of Immune Checkpoint Inhibitor-related Colitis Treated with Infliximab. Society for Immunotherapy of Cancer, 2018.
- Tran C, Abu-Sbeih H, Luo W, Wang y. Vedolizumab achieved clinical and histological remission in a patient with lung cancer who had a steroid-refractory upper gastrointestinal injury due to nivolumab treatment. Society for Immunotherapy of Cancer, 2018.
- Abu-Sbieh H, Tang T, Qiao W, Johnson D, Diab A, Wang Y. Outcomes of immune-checkpoint inhibitor induced organ toxicities. American Society of Clinical Oncology annual meeting (abstract number 10063) 2018, JCO 36, 2018 (suppl; abstr 10063), 2018.
- Abu-Sbeih H, Coronel E, Raju GS, Ross WA, Stroehlein JR, Lee JH, Bhutani M, Wang Y. Endoscopy Is Safe in Cancer Patients with Mild to Moderate Thrombocytopenia. DDW oral presentation 2018, GIE 87(6):AB92-AB93, 2018.
- Abu-Sbeih H, Ali FS, Bhuani MS, Raj GS, Lee Jh, Stroehlein JR, Ross WA, Wang Y. Endoscopy is safe in cancer patients with mild to moderate neutropenia. GIE 87(6):AB128, 2018.
- Abu-Sbieh H, Bhutani MS, Raju GS, Lee JH, Stroehlein JR, Ross WA, Wang Y. Predictors of overall survival in cancer patients who had endoscopic evaluation in the setting of neutropenia and thrombocytopenia. GIE 87(6):AB398-AB399, 2018.
- Abu-Sbeih H, Irshad QUA, Stroehlein JR, Okhuysen PC, Wand Y. Multiple Recurrent Clostridium Difficile Infection Is Associated with Treatment Failure and Prolonged Illness in Cancer Patients. GIE 87(6):AB398-AB399, 2018.
- Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Faju GS, Stroehlein J, Diab A. Immune checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson Cancer Center. GIE 87(6):AB541-AB542, 2018.
- Choi K, Samdani R, Wang Y. Systemic steroids in anti-PD1 induced collagenous colitis. Crohn’s and Colitis Congress meeting, 2018.
- Choi K, Samdani R, Shuttlesworth G, Wang Y. Case series: immunotherapy-induced lymphocytic colitis. Crohn’s and Colitis Congress meeting, 2018.
- Abu-Sbeih H, Shuttlesworth G, Samdani R, Zuazua R, Wang Y. Case series: immune-checkpoint inhibitors induced colitis treated with mesalamine. Crohn’s and Colitis Congress meeting, IBD 24 (suppl_1):S19-S19, 2018.
- Abu-Sbeih H, Shuttlesworth G, Samdani R, Zuazua R, Wang Y. Immuno-checkpoint inhibitor induced colitis in a patient with lung cancer and colon metastasis treated with mesalamine: a case study. Crohn’s and Colitis Congress meeting 2018, IBD 24(suppl_1):S19-S19, 2018.
- Ali F, Samdani R, Wang Y. Short term endoscopic follow up on immune-checkpoint inhibitor induced colitis post treatment. Crohn’s and Colitis Congress meeting, 2018.
- Wang Y, DuPont H, Jian ZD, Jeng R, Zuazua R. Fecal microbiota transplant for immune-checkpoint inhibitor induced colitis in a 50 year old female with bladder cancer. Crohn’s and Colitis Congress meeting, 2018.
- Wang Y, Abu-Sbeih H, Mao E, Ali N, Raju GS, Stroehlein J, Diab A. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. DDW poster 2018, GIE 87(6):AB541-AB542, 2018.
- Ali N, Wang Y, Zuazua R. Patients with immunotherapy induced colitis can benefit from non-immunosuppressive agents. American College of Gastroenterology annual meeting, 2017.
- Wang Y, Samdani R, Campbell M, Abraham S, Cotton I, Zuazua R. A Unique Case of Immunotherapy-Induced Colitis in a 50 Year Old Female with Bladder Cancer. American College of Gastroenterology annual meeting, 2017.
- Wang Y, Samdani R, Bhutani M, Zuazua R, Kebriaei P. A Unique Case of GI GVHD in a 37 year old Male with AML. American College of Gastroenterology annual meeting, 2017.
- Wang Y, Aggarwal P, Liu X, Lu H, Lian L, Wu X, Guo S, Aggarwal N, Lashner B, Shen B. Antiviral Treatment for Colonic Cytomegalovirus Infection in Ulcerative Colitis Patients Significantly Improved Their Surgery Free Survival. Ohio Gastroenterology Society, Columbus, OH, 2016.
- Wang Y, Shen B. Fecal Microbiota Transplantation in Refractory Clostridium Difficile Pouchitis. Crohn's and Colitis Foundation Association, Orlando, FL, 2015.
- Cummings D, Lopez R, Roggenbuck D, Wang Y, Shen B, Rieder F. Serum Anti-GP2 Antibody Isoforms 1 and 4 are Associated with Crohn's Disease of the Pouch in Patients with Ileal-Pouch Anal Anastomosis (IPAA). ACG, Honolulu, HI, 2015.
- Mehta PP, Kochhar G, Albeldawi M, Kirsh B, Rizk M, Putka B, John B, Wang Y, Breslaw N, Lopez R, Vargo JJ. Capnographic Monitoring Does Not Improve Detection of Hypoxemia in Colonoscopy with Moderate Sedation. A Randomized, Controlled Trial. ACG, Philadelphia, PA, 2014.
- Wang Y, Liu X, Lu H, Guo S, Lashner B, Shen B. Treatment for CMV Infection in UC Patients Significantly Decreased the Colectomy Rate. Crohn's and Colitis Foundation Association, Orlando, FL, 2014.
- Asava-aree C, Mu E, Patel V, Feng J, Lian L, Achkar JP, Lashner B, Shen B, Wang Y. CMV Treatment Does Not Improve Clinical Outcomes in IBD Inpatients with CMV Colitis. ACG, San Diego, CA, 2013.
- Wang Y, Bennett AE, Lopez R, Shen B. Endoscopy Alone Is Sufficient for Pouch Disease Activity Monitoring and Prediction of Pouch Outcomes. ACG, San Diego, CA, 2013.
- Wang F, Wang Y. Sclerosing Mesenteritis in a 50-Year-Old Male Successfully Treated with Tamoxifen. ACP, Northern Illinois Regional, Chicago, IL, 2013.
- Lai KK, Wang Y, Zie H, Shen B, Goldblum JR, Lewis BL, Liu X. Clinical Outcome after the Diagnosis of Indefinite for Dysplasia in Patients with Idiopathic Inflammatory Bowel Disease (IBD). United States & Canadian Academy of Pathology, Baltimore, MD, 2013.
- Xie H, X SY, Pai R, Lai K, Wang Y, Shen B, Liu X. Diagnostic Utility of p53 and Cytokeratin 7 Immunohistochemistry in Idiopathic Inflammatory Bowel Disease-Associated Neoplasia. United States & Canadian Academy of Pathology, Baltimore, MD, 2013.
- Mu E, Wu X, Atreja A, Feng J, Shen B, Lashner B, Wang Y. Analysis of Prevalence and Risk Factors for Active Disease of Crohn's Patients for Acute Exacerbation Symptoms. ACG, Las Vegas, NV, 2012.
- Wang F, Jiang W, Pai R, Downs-Kelly E, Wang Y. Helicobacter Heilmannii Infection in A 43-Year-Old Female Effectively Treated with the Standard Triple Therapy. ACP, Chicago, IL, 2012.
- Wang Y, Lee H, Shen B. Secondary Amyloidosis in a 70-Year-Old Patient with Crohn's Disease: Treatment with Oral Budesonide. ACG, Las Vegas, NV, 2012.
- Zhang C, Drazba J, Hatala D, Wang Y, Shen B. A Pilot Study: Development of A Novel Immunostaining Marker for Autoimmune Pouchitis. ACG, Washington, DC, 2011.
- Wang Y, Gong H, Lopez R, Soffer E, Shen B. Correlation between Serum Serotonin and Symptom and Endoscopy Inflammation Scores in Patients with Ileal Pouches. Digestive Disease Week, Chicago, IL, 2011.
- Wang Y, Bennett AE, Cai H, Shen B. Clinical Utility of Duodenal Histology in Diagnosis and Differential Diagnosis of Pouch Disorders. ACG, San Diego, CA, 2009.
- Wang Y, Cai H, Shen B. Clinical Utility of Mucosal Healing in Patients with Pouchitis. ACG, San Diego, CA, 2009.